Evidence map›Paper›PMID 37358628›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network.

Emilio Francesco Giunta, Silvia De Padova, Shobana Anpalakhan, Ugo De Giorgi, Marco Maruzzo, Sara Elena Rebuzzi, Marika Cinausero, Lucia Fratino, Helga Lipari, Teresa Gamba and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 2 countries.

Emilio Francesco GiuntaDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Silvia De PadovaPsycho-Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Shobana AnpalakhanPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.
Ugo De GiorgiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Marco MaruzzoMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Sara Elena RebuzziMedical Oncology Unit, Ospedale San Paolo, Savona, Italy.
Marika CinauseroDepartment of Oncology, ASUFC Santa Maria Della Misericordia, Udine, Italy.
Lucia FratinoDepartment of Medical Oncology, Centro di Riferimento Oncologico di Aviano CRO-IRCCS, Aviano, Italy.
Helga LipariDivision of Medical Oncology, Cannizzaro Hospital, Catania, Italy.
Teresa GambaMedical Oncology, Mauriziano Hospital, Turin, Italy.
Davide BimbattiMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Arianna DriDepartment of Oncology, ASUFC Santa Maria Della Misericordia, Udine, Italy.
Paola ErmacoraDepartment of Oncology, ASUFC Santa Maria Della Misericordia, Udine, Italy.
Francesca VignaniMedical Oncology, Mauriziano Hospital, Turin, Italy.
Umberto BassoMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.
Sebastiano ButiOncology Unit, University Hospital of Parma, Parma, Italy.
Annalice GandiniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Malvina CremanteMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Giuseppe FornariniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Pasquale RescignoCandiolo Cancer Institute, FPO-IRCCS, SP142, km 3,95, 10060, Candiolo, Turin, Italy. Pasquale.rescigno@ircc.it.
Giuseppe Luigi BannaPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.
Istituti di Ricovero e Cura a Carattere Scientifico · ITOspedale Policlinico San Martino · ITOspedale Santa Maria della Misericordia di Udine · ITA. O. Ordine Mauriziano di Torino · ITIstituto Oncologico Veneto · ITPortsmouth Hospitals NHS Trust · GBCandiolo Cancer Institute · ITCentro di Riferimento Oncologico · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale Cannizzaro · ITOspedale San Paolo · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess caregivers' characteristics and influence of the presence or absence of the caregiver on clinical outcomes of older (≥70 years) metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (ABI) or enzalutamide (ENZ).

methodsPatients from the Meet-URO 5 ADHERE study were assessed with a 5-item caregiver evaluation questionnaire focusing on the presence, age, degree of kinship, working status and qualification of the caregiver. We investigated the association between the presence of a caregiver and the clinical characteristics and outcomes of enrolled patients.

resultsNo differences were found in the main clinical characteristics between patients with or without a caregiver, except for a lower median G8 score (p = 0.0453) in the caregiver group. A longer radiographic PFS (rPFS) was observed in the group without a caregiver, with a trend towards more prolonged overall survival (OS) in the same group.

conclusionOur work suggests a detrimental effect of caregivers in managing older mCRPC patients treated with ABI or ENZ, especially those identified as frail by the geriatric G8 screening score. Further work is needed to identify and address patients' vulnerability areas, which could have a detrimental effect on prognosis.

Indexed as

Prostatic Neoplasms, Castration-ResistantAgedCaregiversHumansMaleNitrilesPrognosisProspective StudiesTreatment OutcomeNitrilesCaregiverOlder ageProstate cancerTreatment adherence

Identifiers

PMID37358628
OpenAlexW4382011911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.